Avian influenza: Are our feathers ruffled?

Annals of Saudi Medicine

Volumn 26, Issue 3, 2006, Pages 175-182

  Balkhy, Hanan ^a   Al Hajjar, Sami ^b  

^a KING FAHAD NATIONAL GUARD HOSPITAL   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMANTADINE; CORTICOSTEROID; INFLUENZA VACCINE; OSELTAMIVIR; RIBAVIRIN; RIMANTADINE; ZANAMIVIR;

ARTICLE; AVIAN INFLUENZA; BIRD DISEASE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG SAFETY; EPIDEMIC; GOVERNMENT; HEALTH CARE PLANNING; HOST RESISTANCE; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; INCUBATION TIME; INFECTION CONTROL; INFECTION RESISTANCE; INFECTION RISK; INFLUENZA VIRUS; INFLUENZA VIRUS A; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SAUDI ARABIA; VIRUS STRAIN; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

EID: 33745960384     PISSN: 02564947     EISSN: None     Source Type: Journal    
DOI: 10.5144/0256-4947.2006.175     Document Type: Article

References (34)

1. Beveridge, WIB. The chronicle of influenza epidemics. Hist Phil Life Sci 1991; 223-235.
2. BWHO 2004. World is ill-prepared for "inevitable" flue pandemic. Bull World Health Organ. 2004; 82: 317-318.
3. WHO 2005k. WHO Consultation on the composition of influenza vaccine for the Northern Hemisphere 2006-2007. Accessed May 2006. http://www.who.imt/csr/disease/influenza/vaccinesnorth2006_7/cn/ index.html/
4. Simson L. Pandemic influenza and mortality: Post evidence and projections for the future in: Board on global health. The threat of pandemic influenza: Are we ready? The National Academic Press 2004.
5. Johnson NP, Muller J. Updating the accounts: Global mortality of the 1918-1920. "Spanish" influenza pandemic. Bull Hist Med 2002; 76: 105-15.
6. Poland GA. Vaccine against avian influenza. A race against time. N Engl J Med 2006; 354(13): 1411-13.
7. Dowdle WR. Influenza A virus recycling revisited. Bull World Health Organ 1999; 77: 820-8.
8. Fouchier RA, Munster V, Wallensten A, et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from block headed gulls. J. Virol 2005; 79: 2814-22.
9. Ferguson NM, Galvani AP, Bush RM. Ecological and immunological determinants of influenza evolution. Nature 2003; 442: 428-33.
10. Webster RG, Hulse DJ. Microbial adaptation and change: avian influenza. Rev Sci Tech. 2004; 23: 453-65.
11. Swayne DE, Suarez DL. Highly pathogenic avian influenza. Rev Sci Tech 2000; 19: 463-8.
12. Guan T, Poon LL, Cheum CY et al. H5N1 Influenza: a proteam pandemic threat. Proc Natl Acad Sci USA 2004; 101: 8156-61.
13. Reid AH, Fanning TG, Hultin JV et al. Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene. Proc Natl Acad Sci USA 1999; 96: 1651-6.
14. Kawaoka Y, Krauss S, Webster RG. Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol 1989; 63: 4603-8.
15. Webster RG, Yakhno MA, Hinshaw VS et al. Intestinal influenza: replication and characterization of the influenza virus in ducks. Virology 1978; 84: 268-78.
16. Thanawongnuwech R, Amonsin A, Tantilertcharoen R et al. Probable tiger-to-tiger transmission of avian influenza H5N1. Emerg Infect Dis 2005; 11: 699-701.
17. Banks J, Speidel ES, Moore E, et al. Changes in the haemagglutinin and the neuraminidase genes prior to the emergence of high pathogenic H7N1 avian influenza viruses in Italy. Arch Virol 2001; 456: 963-73.
18. Capua I, Mitenellum F, Merangon S, et al. H7N1 avian influenza in Italy (1999-2000) in intensively reared chicken and turkeys. AV Pathol 2000; 29: 537-43.
19. Bean WJ, Kawaoka Y, Wood JM et al. Characterization of virulent and avirulent A/chicken/Pennsylvania/83 influenza A viruses: potential role of detecting interfering RNAs in nature. J Virol 1958; 54: 151-60.
20. WHO 2004/03/02. Avian influenza A(H5N1)-update 31: Situation (poultry) in Asia: need for a long-term response, comparison with previous outbreaks Accessed May 2006. http://www.who.int/csr/don/2004_03_02/eu/index/html/
21. WHO 2006. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported by WHO. Accessed May 2006. http://www.int.csr.disease/avian_influenza/country/eu.
22. WCWHO 2005. The writing committee of the World Health Organization (WHO) consultation in human influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353: 1374-85.
23. Ungchusakk A, Vewarakul P, Dowel SF et al. Probable person-to-person transmission of avian influenza: A (H5N1). N Engl J 2005; 352: 333-40.
24. Chot P, Tayasumond HT, Ungchusakk A, Hanshaoworakal U, et al. Human disease from influenza A (H5N1) Thailand 2004. Emerg Infect Dis 2005; 11: 201-9.
25. de Jong MD, Back VC, Paht Q et al. Fatal avian influenza A (H5N1) in child presenting with diarrhea followed by coma. N Engl J Med 2005; 352: 686: 91.
26. Yuen KY, Chan PK, Peris M, et al. Clinical feature and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998; 351: 467-71.
27. WHO 2005: WHO global influenza preparedness plan: The role of WHO and recommendations for national measures before and during pandemics. Accessed May 2006. http://www.who.int/entity/csr/resources/publications/influenza/ WHO_CDS_CSR_GIP_2005_5/en/index.html
28. CDC Fact Sheet. Antiviral Agents for Influenza: Background Information for Clinicians. http://www.cdc.gov/flu/professionals/antiviralback.htm. Last modified March 31, 2006
29. Hayden FG. Antivirals for pandemic influenza. IV peramivir in influenza A/duck/MN/1525/81 (H5N1) infection in mice. Presented at Second International Conference on Community-Acquired Pneumonia, Montreal, Sept 17-19, 2005. www.shea-online.org/Assets/files/ W_-_Antivirals_for_Pandemic_Influenza.ppt
30. Leneva IA, Goloubeva O, Fenton RJ, et al. Efficacy of Zanamavir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob Agents Chemoth 2001; 45: 1216:24.
31. Cheung C-L, Rayner JM, Smith GJD, et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 2006; 193: 1626-1629.
32. WHO 2006. Infection control recommendations for avian influenza in health care facilities. Accessed May 2006. http://www.who.int.csr/
33. WHO 2004. WHO interim guidelines on clinical management of humans infected by influenza A (H5N1). Accessed May 2006. http://www.who.int/csr/disease_avia_influenza/guidelines/clinicalmanage/ eu/index.html/
34. Treanor JJ, Campbell JD, Zangwill KM et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354(13): 1343-51.